Medifast (NYSE:MED) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Shares of Medifast Inc (NYSE:MED) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.21 and traded as high as $12.20. Medifast shares last traded at $12.0260, with a volume of 62,331 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Zacks Research lowered Medifast from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $12.00.

Medifast Trading Down 0.0%

The stock has a market capitalization of $133.99 million, a P/E ratio of -5.14 and a beta of 0.71. The business’s fifty day simple moving average is $11.36 and its two-hundred day simple moving average is $11.22.

Medifast (NYSE:MED) last posted its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The company had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, equities research analysts anticipate that Medifast Inc will post -1.04 earnings per share for the current year.

Insider Activity at Medifast

In other news, Director Parsa Kiai acquired 43,150 shares of Medifast stock in a transaction on Wednesday, August 26th. The stock was bought at an average price of $12.26 per share, for a total transaction of $529,019.00. Following the transaction, the director owned 707,492 shares of the company’s stock, valued at $8,673,851.92. The trade was a 6.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 119,966 shares of company stock valued at $1,423,576. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Medifast

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Medifast during the second quarter valued at $3,920,000. Bank of America Corp DE bought a new stake in shares of Medifast in the 2nd quarter worth about $924,000. Empowered Funds LLC bought a new stake in shares of Medifast in the 2nd quarter worth about $701,000. Great Lakes Advisors LLC acquired a new stake in shares of Medifast during the 2nd quarter worth about $548,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Medifast during the 2nd quarter worth about $408,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.